idecabtagene vicleucel
AXP000017.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- TNFRSF17
- Originator
- bluebird bio
- Sponsor
- Bristol Myers Squibb
Names
| Name | Type | Source |
|---|---|---|
| idecabtagene vicleucel | preferred name, INN | curator, ncit |
| Abecma | brand | ncit |
| bb2121 | code | ncit |
| ide-cel | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- replication-incompetent lentiviral vector carrying the anti-BCMA02 CAR; murine extracellular scFv against BCMA, human CD8 alpha hinge and transmembrane domain, CD137 (4-1BB) and CD3 zeta cytoplasmic domains fused in tandem
- Transgenes
- anti-BCMA chimeric antigen receptor
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C117729
- Wikidata
- Q106293994
- FDA UNII
- 8PX1X7UG4D
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2021-03-26 | approved | Abecma | Adults with relapsed or refractory multiple myeloma after two or more prior lines including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody | source |
| EMA | EU | 2021-08-18 | approved | Abecma | Adults with relapsed and refractory multiple myeloma after at least two prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, who progressed on the last therapy | source |
| PMDA | JP | 2022-01-20 | approved | Abecma | Relapsed or refractory multiple myeloma in patients with no prior BCMA-directed CAR T-cell therapy who have had at least three prior lines including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and who progressed after the last of them | source |
Clinical trials (19)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06523621 | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | Active not recruiting | Phase 2 | 2025-02-28 | 2026-03-21 | 1 | Multiple Myeloma |
| NCT06855121 | The Norwegian Immunotherapy in Multiple Myeloma Study | Recruiting | 2025-01-15 | 2029-01 | 400 | AL Amyloidosis; Myeloma Multiple; Plasma Cell Leukemia | |
| NCT06518551 | ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma | Recruiting | Phase 1 | 2024-11-01 | 2029-12-31 | 24 | Multiple Myeloma; Myeloma; Refractory Multiple Myeloma |
| NCT06698887 | A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea | Recruiting | 2024-09-11 | 2031-03-27 | 15 | Multiple Myeloma | |
| NCT06179888 | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Suspended | Phase 2 | 2024-08-27 | 2030-03-01 | 84 | Multiple Myeloma |
| NCT06048250 | Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | Active not recruiting | Phase 1 | 2024-04-09 | 2027-02-09 | 15 | Multiple Myeloma |
| NCT06045806 | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | Active not recruiting | Phase 3 | 2023-10-16 | 2025-08-11 | 79 | Multiple Myeloma |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | Recruiting | 2023-10-06 | 2038-10-06 | 50 | Chronic Lymphocytic Leukaemia; Multiple Myeloma; Non-Hodgkin Lymphoma | |
| NCT06154902 | Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel | Active not recruiting | 2022-07-29 | 2027-07-31 | 350 | Multiple Myeloma | |
| NCT05393804 | A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant | Active not recruiting | Phase 2 | 2022-05-20 | 2027-05 | 24 | Multiple Myeloma |
| NCT05032820 | Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | Completed | Phase 2 | 2022-01-05 | 2024-08-22 | 40 | Multiple Myeloma |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma | Terminated | Phase 1 | 2021-06-01 | 2025-04-25 | 21 | Multiple Myeloma |
| NCT04196491 | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | Completed | Phase 1 | 2020-05-27 | 2023-06-07 | 13 | Multiple Myeloma |
| NCT03651128 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | Completed | Phase 3 | 2019-04-16 | 2026-04-13 | 386 | Multiple Myeloma |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Active not recruiting | Phase 2 | 2018-12-18 | 2024-02-09 | 150 | Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
| NCT03601078 | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | Completed | Phase 2 | 2018-12-13 | 2026-01-15 | 312 | Multiple Myeloma |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma | Completed | Phase 2 | 2017-12-13 | 2023-12-20 | 149 | Multiple Myeloma |
| NCT02658929 | Study of bb2121 in Multiple Myeloma | Completed | Phase 1 | 2015-12-22 | 2019-07-22 | 67 | Multiple Myeloma |
| NCT04771078 | Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release | Available | Multiple Myeloma |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT02786511 | Longterm Follow-up of Subjects Treated With bb2121 | Completed | 2016-04-28 | 2019-10-11 | 50 | Multiple Myeloma | name in title: bb2121 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41485914 | An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression. | Internal medicine (Tokyo, Japan) | 2026 | name in title: idecabtagene vicleucel |
| PMID 41627370 | Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. | Advances in therapy | 2026 | cited by trial NCT03651128 |
| PMID 41859580 | Myelodysplastic Syndrome Secondary to Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma. | Cureus | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41894689 | Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM. | Blood advances | 2026 | cited by trial NCT04771078 |
| PMID 41914448 | Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis. | American journal of hematology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42084945 | Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. | JCI insight | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42284467 | Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. | Blood cancer discovery | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42392508 | Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma. | Transplantation and cellular therapy | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42645380 | Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42747560 | Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma. | Annals of hematology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 39965175 | Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | name in title: idecabtagene vicleucel |
| PMID 40178605 | Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma. | Annals of hematology | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40198886 | Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. | Blood | 2025 | cited by trial NCT03361748 |
| PMID 40461939 | Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. | Clinical pharmacokinetics | 2025 | name in title: idecabtagene vicleucel |
| PMID 40514575 | A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review. | International journal of hematology | 2025 | name in title: idecabtagene vicleucel |
| PMID 40641008 | Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. | Journal of clinical pharmacology | 2025 | name in title: idecabtagene vicleucel |
| PMID 40665490 | Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma. | British journal of haematology | 2025 | name in title: idecabtagene vicleucel |
| PMID 40684380 | Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis. | Hematological oncology | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40738883 | Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement. | Blood cancer journal | 2025 | name in abstract: ide-cel |
| PMID 40749169 | Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. | Blood | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40875887 | Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. | Blood advances | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40972962 | Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium. | Transplantation and cellular therapy | 2025 | name in title: idecabtagene vicleucel |
| PMID 37855036 | Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. | Haematologica | 2024 | name in title: idecabtagene vicleucel |
| PMID 38263627 | Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. | British journal of haematology | 2024 | name in title: idecabtagene vicleucel |
| PMID 38423700 | Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. | The Lancet. Haematology | 2024 | name in title: idecabtagene vicleucel |
| PMID 38534054 | Successful Treatment of Refractory Orbital Plasmacytoma with Chimeric Antigen Receptor T Cell Therapy: A Case Report and Review of the Literature. | Ophthalmic plastic and reconstructive surgery | 2024 | name in abstract: idecabtagene vicleucel |
| PMID 38651976 | Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. | Future oncology (London, England) | 2024 | cited by trial NCT03651128 |
| PMID 38747092 | French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry. | British journal of haematology | 2024 | name in title: idecabtagene vicleucel |
| PMID 38776397 | Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. | Blood advances | 2024 | name in abstract: idecabtagene vicleucel |
| PMID 38834151 | Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. | Transplantation and cellular therapy | 2024 | name in title: idecabtagene vicleucel |
| PMID 38845015 | Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. | Journal of hematology & oncology | 2024 | name in title: idecabtagene vicleucel |
| PMID 39042903 | Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. | Blood advances | 2024 | name in title: idecabtagene vicleucel |
| PMID 39100867 | Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases. | Kidney medicine | 2024 | name in abstract: idecabtagene vicleucel |
| PMID 39197072 | Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. | Blood | 2024 | cited by trial NCT03651128 |
| PMID 39379098 | EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. | Journal for immunotherapy of cancer | 2024 | name in title: ide-cel |
| PMID 39588407 | Local Cytokine Release Syndrome After Idecabtagene Vicleucel Therapy in Patients With Multiple Myeloma: Two Case Reports. | Cureus | 2024 | name in title: idecabtagene vicleucel |
| PMID 36690910 | Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. | International journal of hematology | 2023 | name in title: idecabtagene vicleucel |
| PMID 36705644 | Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France. | Journal of medical economics | 2023 | cited by trial NCT03361748 |
| PMID 36762851 | Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. | The New England journal of medicine | 2023 | cited by trial NCT03651128 |
| PMID 36794354 | Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. | CPT: pharmacometrics & systems pharmacology | 2023 | cited by trial NCT03361748 |
| PMID 37087950 | Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. | Leukemia research | 2023 | cited by trial NCT03361748 |
| PMID 37307173 | Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. | Blood advances | 2023 | name in title: idecabtagene vicleucel |
| PMID 37348705 | Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation. | Transplantation and cellular therapy | 2023 | name in title: idecabtagene vicleucel |
| PMID 37436678 | Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma. | International journal of hematology | 2023 | name in abstract: idecabtagene vicleucel |
| PMID 37558706 | Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. | Blood cancer journal | 2023 | name in title: ide-cel |
| PMID 37592106 | Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. | Nature medicine | 2023 | cited by trial NCT02658929 |
| PMID 37597153 | Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial. | Advances in therapy | 2023 | name in title: idecabtagene vicleucel |
| PMID 37999117 | Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. | Current oncology (Toronto, Ont.) | 2023 | name in abstract: ide-cel |
| PMID 34933328 | Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. | Blood advances | 2022 | cited by trial NCT03361748 |
| PMID 35046063 | FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | cited by trial NCT03361748 |
| PMID 35485211 | Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. | Journal of comparative effectiveness research | 2022 | cited by trial NCT03361748 |
| PMID 35939783 | Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. | Blood advances | 2022 | name in title: idecabtagene vicleucel |
| PMID 33565700 | Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T. | CPT: pharmacometrics & systems pharmacology | 2021 | name in abstract: bb2121 |
| PMID 33619368 | Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. | Nature medicine | 2021 | cited by trial NCT03361748 |
| PMID 33626253 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. | The New England journal of medicine | 2021 | name in title: idecabtagene vicleucel |
| PMID 34145225 | KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. | Blood cancer journal | 2021 | name in title: idecabtagene vicleucel |
| PMID 34256668 | Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. | Current medical research and opinion | 2021 | name in title: idecabtagene vicleucel |
| PMID 34549906 | From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma? | Cancer journal (Sudbury, Mass.) | 2021 | cited by trial NCT04196491 |
| PMID 31042825 | Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. | The New England journal of medicine | 2019 | name in title: bb2121 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39410883 | Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. | Expert opinion on drug safety | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 40966637 | Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. | Blood advances | 2026 | name in title: ide-cel |
| PMID 41284631 | Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data. | Blood | 2026 | name in title: idecabtagene vicleucel |
| PMID 41349540 | A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. | Cancer cell | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41391508 | Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study. | Transplantation and cellular therapy | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41396346 | Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. | PharmacoEconomics - open | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41396414 | Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma. | International journal of hematology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41428622 | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turkish journal of haematology : official journal of Turkish Society of Haematology | 2026 | name in abstract: ide-cel |
| PMID 41448297 | Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis. | Critical reviews in oncology/hematology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41455805 | CAR T-cells in multiple myeloma: the race to the start line. | Bone marrow transplantation | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41540109 | CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. | Nature medicine | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41563628 | Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status? | Targeted oncology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41687609 | The cellular orchestra of CAR T success. | Cancer cell | 2026 | name in abstract: ide-cel |
| PMID 41720163 | Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates. | Transplantation and cellular therapy | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41721717 | Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma. | Hematological oncology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41744844 | BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41748023 | Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes. | Transplantation and cellular therapy | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41777657 | Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice. | Frontiers in oncology | 2026 | name in abstract: ide-cel |
| PMID 41791576 | Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma. | Transplantation and cellular therapy | 2026 | name in title: idecabtagene vicleucel |
| PMID 41869788 | Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity. | Leukemia & lymphoma | 2026 | name in title: idecabtagene vicleucel |
| PMID 41870621 | Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database. | Annals of hematology | 2026 | name in abstract: ide-cel |
| PMID 41886632 | Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma. | Blood advances | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 41899614 | Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients. | Cancers | 2026 | name in title: idecabtagene vicleucel |
| PMID 41951449 | Infections Post-CAR-T Therapy: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database. | Clinical therapeutics | 2026 | name in abstract: ide-cel |
| PMID 41974660 | Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. | Blood cancer journal | 2026 | name in title: idecabtagene vicleucel |
| PMID 41975476 | CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting. | Journal of hematology & oncology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42086512 | Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis. | American journal of hematology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42115674 | Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma. | Bone marrow transplantation | 2026 | name in title: idecabtagene vicleucel |
| PMID 42128857 | [Clinical outcomes of idecabtagene vicleucel therapy for relapsed/refractory multiple myeloma: a single-center retrospective analysis]. | [Rinsho ketsueki] The Japanese journal of clinical hematology | 2026 | name in title: idecabtagene vicleucel |
| PMID 42144192 | Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma. | Transplantation and cellular therapy | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42169662 | Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients. | Hematology/oncology and stem cell therapy | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42198343 | Signal Detection and Machine Learning-Based Prediction of Cytokine Release Syndrome in B-Cell Maturation Antigen-Targeting Immunotherapies Using FAERS Data. | Pharmaceuticals (Basel, Switzerland) | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42208766 | Delay differential equation modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies. | Journal of pharmaceutical sciences | 2026 | name in title: ide-cel |
| PMID 42227265 | Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience. | British journal of haematology | 2026 | name in title: idecabtagene vicleucel |
| PMID 42257064 | Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report. | Case reports in hematology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42269145 | Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. | Cancer immunology research | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42275255 | Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma. | Blood | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42302965 | Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival. | Transplantation and cellular therapy | 2026 | name in title: idecabtagene vicleucel |
| PMID 42317206 | CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma. | HemaSphere | 2026 | name in title: idecabtagene vicleucel |
| PMID 42345308 | A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma. | Current medical research and opinion | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42364732 | Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. | Transplantation and cellular therapy | 2026 | name in title: idecabtagene vicleucel |
| PMID 42396130 | Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma. | HemaSphere | 2026 | name in title: idecabtagene vicleucel |
| PMID 42415719 | Immune Effector Cell-Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene-Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting. | EJHaem | 2026 | name in title: idecabtagene vicleucel |
| PMID 42418682 | Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma. | Blood | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42449578 | Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma. | Cancers | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42463487 | Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma. | Blood cancer journal | 2026 | name in title: idecabtagene vicleucel |
| PMID 42471153 | Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42512374 | Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis. | Cancers | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42518303 | Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort. | Leukemia & lymphoma | 2026 | name in abstract: ide-cel |
| PMID 42528274 | Engineering Soluble Recombinant BCMA for Ide-Cel Labeling. | European journal of immunology | 2026 | name in title: ide-cel |
| PMID 42542408 | Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma. | Clinical lymphoma, myeloma & leukemia | 2026 | name in title: idecabtagene vicleucel |
| PMID 42618275 | Diagnostic Tissue Re-Evaluation Supporting the Observation of a 11C-Methionine PET-Negative Residual Paraskeletal Mass in Multiple Myeloma. | Internal medicine (Tokyo, Japan) | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42625595 | Post-CAR T-cell thyroid dysfunction: destructive thyroiditis identified through thyroid function monitoring in a single-center cohort. | Frontiers in oncology | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42644320 | Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria. | British journal of haematology | 2026 | name in title: ide-cel |
| PMID 42657922 | Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses. | Haematologica | 2026 | name in title: idecabtagene vicleucel |
| PMID 42660229 | Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Myeloma: A Single-Center Real-World Experience. | Transplantation and cellular therapy | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42705499 | Delayed Neurologic and Enterocolitis Reporting Patterns for Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in EudraVigilance. | Transplantation and cellular therapy | 2026 | name in title: idecabtagene vicleucel |
| PMID 42709039 | Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan. | Journal of medical economics | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42724501 | Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143. | Translational cancer research | 2026 | name in title: ide-cel |
| PMID 42759984 | Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products. | Journal for immunotherapy of cancer | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42844744 | Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42901918 | The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program. | Nature communications | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 42908664 | Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database. | Frontiers in pharmacology | 2026 | name in abstract: Abecma |
| PMID 42936704 | Prognostic value of simultaneous [18F]FDG-PET/MRI in refractory multiple myeloma treated with anti-BCMA CAR T. | HemaSphere | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 43026080 | Secondary cancer after CAR-T cell therapy: A French pharmacovigilance analysis. | Therapie | 2026 | name in abstract: idecabtagene vicleucel |
| PMID 38718775 | Toxicity of CAR T-Cell Therapy for Multiple Myeloma. | Acta haematologica | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 39373355 | B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice. | The Annals of pharmacotherapy | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 39528086 | Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 39651553 | Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma. | Expert opinion on biological therapy | 2025 | name in title: idecabtagene vicleucel |
| PMID 39672542 | Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. | Transplantation and cellular therapy | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 39729503 | BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. | Blood advances | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 39748220 | Update on B-cell maturation antigen-directed therapies in AL amyloidosis. | British journal of haematology | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 39779930 | T cell malignancies after CAR T cell therapy in the DESCAR-T registry. | Nature medicine | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 39786391 | Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. | Blood advances | 2025 | name in title: idecabtagene vicleucel |
| PMID 39822585 | Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. | HemaSphere | 2025 | name in title: idecabtagene vicleucel |
| PMID 39846935 | Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome. | Cytotherapy | 2025 | name in title: idecabtagene vicleucel |
| PMID 39938011 | Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma. | Blood advances | 2025 | name in title: idecabtagene vicleucel |
| PMID 39990276 | Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy. | Cancer management and research | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40053892 | Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | name in title: idecabtagene vicleucel |
| PMID 40166474 | Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients. | Frontiers in pharmacology | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40198765 | Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. | Blood advances | 2025 | name in title: idecabtagene vicleucel |
| PMID 40225701 | Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. | ClinicoEconomics and outcomes research : CEOR | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40246942 | CAR-T for multiple myeloma: practice pearls. | Bone marrow transplantation | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40257295 | Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma. | Transplant infectious disease : an official journal of the Transplantation Society | 2025 | name in title: idecabtagene vicleucel |
| PMID 40330632 | Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell Therapy. | EJHaem | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40346502 | Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. | BMC cancer | 2025 | name in abstract: ide-cel |
| PMID 40465403 | FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in title: idecabtagene vicleucel |
| PMID 40485666 | Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies. | Therapeutic advances in drug safety | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40504993 | Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. | Blood | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40534492 | Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. | Haematologica | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40546722 | Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma. | Blood neoplasia | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40610432 | Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. | Nature communications | 2025 | name in title: idecabtagene vicleucel |
| PMID 40619794 | Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods. | Balkan medical journal | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40626006 | Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure. | Frontiers in oncology | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40638198 | Real-world data provide a CARbon copy for ide-cel. | Blood | 2025 | name in title: ide-cel |
| PMID 40644619 | Sequential BCMA CAR T-cell therapy in refractory multiple myeloma. | Blood advances | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40671605 | Chimeric antigen receptor T-cell therapy for multiple myeloma. | Current opinion in oncology | 2025 | name in abstract: idecabtagene vicleucel |
| PMID 40672475 | Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses. | medRxiv : the preprint server for health sciences | 2025 | name in title: ide-cel |
| PMID 40674751 | Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy? | Blood advances | 2025 | name in title: ide-cel |
| PMID 40680848 | Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma. | Transplantation and cellular therapy | 2025 | name in abstract: idecabtagene vicleucel |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC011439 | Development of Chimeric Antigen Receptors Targeting Multiple Myeloma | DIVISION OF BASIC SCIENCES - NCI | KOCHENDERFER, JAMES | 2024–2024 | name in abstract: idecabtagene vicleucel |
| U01AI113362 | Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE) | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | VINCENTI, FLAVIO | 2021–2023 | name in abstract: ide-cel |
| U01FD007937 | Development of novel methods to enable robust comparison of real-world Progression Free Survival (rwPFS) and Clinical Trial PFS in Multiple Myeloma | JANSSEN RESEARCH & DEVELOPMENT, LLC | SARSOUR, KHALED | 2023–2023 | name in abstract: Abecma |
Notes
Anti-BCMA 4-1BB CAR; co-developed by bluebird bio (later 2seventy bio) and Celgene/BMS.
How to cite
idecabtagene vicleucel (AXP000017.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000017.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.